Equities Analysts Issue FY2024 Earnings Forecasts for Galapagos NV (NASDAQ:GLPG)

Galapagos NV (NASDAQ:GLPG – Free Report ) – Stock analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Galapagos in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the biotech company will earn $0.08 per share for the year. Leerink Partners currently has a “Hold” rating on the stock. The consensus estimate for Galapagos’ current full-year earnings is $0.82 per share. Leerink Partnrs also issued estimates for Galapagos’ Q4 2024 earnings at ($0.17) EPS and FY2026 earnings at ($2.06) EPS.

A number of other analysts have recently issued reports on the stock. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Leerink Partners assumed coverage on shares of Galapagos in a research note on Monday. They set a “market perform” rating and a $24.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $31.00, based on data from MarketBeat.

See the latest Galapagos stock report

Galapagos price performance

Shares of NASDAQ:GLPG opened at $28.99 on Tuesday. The company has a 50 day moving average of $26.64 and a two hundred day moving average of $28.71. Galapagos has a 12 month low of $24.16 and a 12 month high of $42.46.

Hedge funds are affecting the Galapagos

A number of large investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA raised its position in shares of Galapagos by 0.7% in the second quarter. Primecap Management Co. CA now owns 720,240 shares of the biotechnology company’s stock valued at $17,848,000 after buying an additional 5,000 shares during the period. Wellington Management Group LLP boosted its holdings in Galapagos by 3.9% in the fourth quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock worth $20,131,000 after buying an additional 18,552 shares in the last quarter. Stonepine Capital Management LLC grew its stake in Galapagos by 23.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock worth $12,018,000 after buying an additional 91,366 shares. of shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Galapagos by 5.3% in the second quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company’s stock valued at $8,466,000 after acquiring an additional 17,089 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Galapagos by 1.6% in the second quarter. Renaissance Technologies LLC now owns 270,800 shares of the biotechnology company’s stock valued at $6,710,000 after acquiring an additional 4,300 shares during the last quarter. 32.46% of the shares are currently owned by institutional investors and hedge funds.

Galapagos Company Profile

(Get a free report)

Galapagos NV, a biotechnology company, develops drugs focusing on oncology and immunology primarily in the United States and Europe. The company’s products include GLPG3667 which has completed a phase 1b trial; GLPG5101, a point-of-care CD19 CAR-T product candidate currently in Phase 1/2 study in relapsed/refractory non-Hodgkin lymphoma; GLPG5201, a point-of-care CD19 CAR-T product candidate, currently in a Phase 1/2 trial in relapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a point-of-care BCMA CAR-T product candidate currently in Phase 1/2 in relapsed/refractory multiple myeloma.

See Also

Get news and reviews for Galapagos Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Galapagos and related companies with MarketBeat.com’s FREE daily email newsletter.